The technology platform company creating the new standard for real-world data and analytics, Komodo Health, is partnering with AppliedVR, a leading innovator of therapeutic virtual reality solutions for pain management.
AppliedVR was recently granted its De Novo request for its flagship product, RelieVRx. The company is now leveraging Komodo’s technology platform to evaluate and showcase the therapeutic impact of RelieVRx for patients suffering from chronic lower back pain. The two entities look to combine AppliedVR’s proprietary insights with Komodo’s real-world data to facilitate research into the efficacy, cost savings, and health system value that RelieVRx offers instead of traditional chronic pain treatments.
The comprehensive view of real-world patient experiences will help AppliedVR draw more insights from the impact of its treatment methods for subsets of the patient population, examine the healthcare resource utilization of patients, and gauge the clinical impact and cost-effectiveness of RelieVRx.
“With the power of the Komodo platform, we are gaining important insights into the value that RelieVRx delivers beyond the patient-reported outcomes collected from clinical trials, and we are quantifying the impact we can deliver for stakeholders across the industry,” said Josh Sackman, President and Co-founder at AppliedVR.
Komodo’s technology will help the AppliedVR research team to look beyond the conventional self-reported pain levels and better understand the impact of RelieVRx on variables such as surgery rates, chiropractic visits, opioid prescription volume, and more.
“AppliedVR is at the cutting edge of pain management, not only developing innovative technologies but applying comprehensive research rigor to prove the value of the therapy for those suffering from chronic pain,” said Komodo Health President and Co-founder, Web Sun.
The findings from the research and the accompanying studies will help demonstrate the real-world clinical and economic value of therapy through VR-powered technologies. RelieVRx is the first and only VR-based chronic pain therapy to receive De Novo approval from FDA. The prescription-use immersive virtual reality system aims to provide adjunctive treatment for patients suffering from moderate to severe chronic lower back pain.